A multi-center phase I/II study of melphalan, prednisone, thalidomide and defibrotide in avanced multiple myeloma patients.

被引：3
|
作者：
Palumbo, Antonio
Rus, Cecilia
Rossi, Davide
Pregno, Patrizia
Ambrosini, Maria Teresa
Avonto, Ilaria
Gay, Francesca
Cavallo, Federica
Iacobelli, Massimo
Gaidano, Gianluca
Mitsiades, Constantine
Richardson, Paul G.
Anderson, Kenneth C.
Boccadoro, Mario
机构：
[1] Univ Turin, Azienda Osped San Giovanni Battista, Div Ematol, Turin, Italy
[2] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
10.1182/blood.V108.11.3560.3560
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3560
引用
收藏
页码：1016A / 1017A
页数：2
相关论文
共 50 条
  • [21] Erratum: Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant-ineligible patients with multiple myeloma: a meta-analysis
    P Kapoor
    S V Rajkumar
    A Dispenzieri
    M A Gertz
    M Q Lacy
    D Dingli
    J R Mikhael
    V Roy
    R A Kyle
    P R Greipp
    S Kumar
    S J Mandrekar
    Leukemia, 2011, 25 : 1523 - 1524
  • [22] A phase I/II multi-center study of Troxatyl™ in patients with refractory chronic lymphocytic leukemia (CLL), lymphoma or multiple myeloma (MM).
    Giles, F
    Belanger, R
    Toor, A
    McLaughlin, P
    Fayad, L
    Beran, M
    Albitar, M
    Vose, J
    BLOOD, 2001, 98 (11) : 289B - 289B
  • [23] Phase III Study of the Value of Thalidomide Added to Melphalan Plus Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma: The HOVON 49 Study
    Wijermans, Pierre
    Schaafsma, Martijn
    Termorshuizen, Fabian
    Ammerlaan, Rianne
    Wittebol, Shulamiet
    Sinnige, Harm
    Zweegman, Sonja
    Kooy, Marinus van Marwijk
    van der Griend, Rene
    Lokhorst, Henk
    Sonneveld, Pieter
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) : 3160 - 3166
  • [24] Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study
    Morabito, Fortunato
    Bringhen, Sara
    Larocca, Alessandra
    Wijermans, Pierre
    Victoria Mateos, Maria
    Gimsing, Peter
    Mazzone, Carla
    Gottardi, Daniela
    Omede, Paola
    Zweegman, Sonja
    Jose Lahuerta, Juan
    Zambello, Renato
    Musto, Pellegrino
    Magarotto, Valeria
    Schaafsma, Martijn
    Oriol, Albert
    Juliusson, Gunnar
    Cerrato, Chiara
    Catalano, Lucio
    Gentile, Massimo
    Isabel Turel, Ana
    Liberati, Anna Marina
    Cavalli, Maide
    Rossi, Davide
    Passera, Roberto
    Rosso, Stefano
    Beksac, Meral
    Cavo, Michele
    Waage, Anders
    San Miguel, Jesus
    Boccadoro, Mario
    Sonneveld, Pieter
    Palumbo, Antonio
    Offidani, Massimo
    AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (04) : 355 - 362
  • [25] Melphalan-prednisone-thalidomide to newly diagnosed patients with multiple myeloma: A placebo controlled randomised phase 3 trial
    Waage, Anders
    Gimsing, Peter
    Juliusson, Gunnar
    Turesson, Ingemar
    Fayers, Peter
    BLOOD, 2007, 110 (11) : 32A - 32A
  • [26] Melphalan, prednisone and thalidomide (MPT) versus melphalan and prednisone (MP) in newly diagnosed myeloma: Results of a prospective, randomized phase III study
    Bringhen, S.
    Liberati, A. M.
    Caravita, T.
    Falcone, A.
    Dore, F.
    Carubelli, A.
    Elice, F.
    Griso, L.
    Foli, C.
    Darbesio, A.
    Baraldi, A.
    Cellini, C.
    Annino, L.
    Piro, E.
    Magarotto, V
    Avonto, I
    Musto, P.
    Boccadoro, M.
    Palumbo, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 135 - 136
  • [27] A RANDOMIZED PHASE II STUDY (GISL-MM03 TRIAL) WITH ORAL MELPHALAN plus PREDNISONE (MP) VERSUS MELPHALAN, plus PREDNISONE plus THALIDOMIDE (MPT) FOR NEWLY DIAGNOSED ELDERLY PATIENTS WITH MULTIPLE MYELOMA
    Sacchi, S.
    Marcheselli, R.
    Pozzi, S.
    Bari, A.
    Ciarcia, O.
    Masini, L.
    Lazzaro, A.
    Morabito, F.
    Fragasso, A.
    Di Renzo, N.
    Quarta, G.
    Buda, G.
    Musto, P.
    Vigliotti, M. L.
    Pastorini, A.
    Brugiatelli, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 384 - 384
  • [28] Combination of Lenalidomide, Melphalan, Prednisone and Thalidomide (RMPT) in Relapsed/Refractory Multiple Myeloma: Results of a Multicenter Phase II Clinical Trial
    Palumbo, Antonio
    Falco, Patrizia
    Sanpaolo, Grazia
    Falcone, Antonietta
    Ferderico, Vincenzo
    Canepa, Letizia
    Crugnola, Monica
    Baldini, Luca
    Larocca, Alessandra
    Magarotto, Valeria
    Petrucci, Maria Teresa
    Boccadoro, Mario
    BLOOD, 2008, 112 (11) : 321 - 321
  • [29] Updated results of a phase 2 study of panobinostat combined with melphalan, thalidomide and prednisone (MPT) in relapsed/refractory multiple myeloma
    Offidani, Massimo
    Corvatta, Laura
    Liberati, Anna Marina
    Pulini, Stefano
    Ballanti, Stelvio
    Bringhen, Sara
    LEUKEMIA & LYMPHOMA, 2018, 59 (05) : 1271 - 1273
  • [30] A Prospective, Randomized, Phase III Study of Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) Versus Bortezomib, Melphalan and Prednisone (VMP) in Elderly Newly Diagnosed Myeloma Patients
    Palumbo, Antonio
    Bringhen, Sara
    Rossi, Davide
    Magarotto, Valeria
    Di Raimondo, Francesco
    Ria, Roberto
    Offidani, Massimo
    Nozzoli, Chiara
    Patriarca, Francesca
    Callea, Vincenzo
    Benevolo, Giulia
    Marasca, Roberto
    Guglielmelli, Tommasina
    Rizzo, Manuela
    Grasso, Mariella
    Petrucci, Maria Teresa
    Omede, Paola
    Gaidano, Gianluca
    Boccadoro, Mario
    BLOOD, 2008, 112 (11) : 243 - 243
12345